Can We Short-Circuit the Signals That Drive Cancer?

Exploring a Potential New Class of Cancer Drug: Super-Enhancer Modulators

NextGen Scientific's lead candidate, GZ17-6.02, is being developed as a super-enhancer modulator. Instead of blocking a single target, it regulates the genetic programs that drive cancer. Therapies that act on gene regulation rank among oncology's fastest-growing categories, with the global epigenetics market projected to reach about $72 billion by 2034, up from roughly $20 billion in 2025.[1]

Co-Founder Jason West sits down with Ben DiScipio of Texture Capital for Beyond Drug Development: A Better Life Sciences Business Model. Where the company stands, what it is building next, and what that means for shareholders. Bring questions. The Q&A is open.

Date

Tuesday, August 25

Time

4:00 PM PT / 7:00 PM ET

Format

Online, with Q&A

Registration Seats open

Reserve Your Seat

Add your name and we will send the join link plus a calendar hold. Cannot attend on the day? Register anyway and we will send the replay.

On the agenda

Sixty Minutes, Five Topics, One Unfiltered Q&A

Management walks through the business, then opens the floor. Ask what you want to ask.

Where the Business Stands

Recent developments and the milestones the company has cleared since its last update.

Oncology and Life Sciences Progress

Movement across the drug program and the rest of the portfolio, explained in plain terms.

Growth and Commercial Expansion

How the company plans to expand from here, and the reasoning behind the order it is doing things in.

What Comes Next for Shareholders

The road ahead, the near-term priorities, and how leadership measures its own progress.

Live Q&A with Management

Your question goes straight to the people making the decisions.

Who you will hear from

Featured Speakers

Jason West, JD, MBA

Co-Founder & Executive Vice President

Jason ran an oilfield chemical company through a nine-figure sale before turning to life sciences. He handles strategy, structure, and the legal side of how NextGen is built.

Former President, Jacam Chemical Company
Biology degree, Sterling College
Juris Doctor, Vermont Law School
MBA, Northwestern University

Ben DiScipio

Texture Capital

Ben works with private issuers on capital markets and investor relations at Texture Capital, a FINRA member broker-dealer. He moderates the session and keeps management on the questions investors actually care about.

Why this one is worth an hour

Upstream of the Target, Not at It

Most cancer therapies shut down one protein and wait to see how long the tumor takes to route around it. Super-enhancers sit higher up the chain, switching whole sets of genes on and off. That is the level GZ17-6.02 is designed to work at, and it is where an increasing share of oncology research money has been heading.

A Mechanism with Room to Travel

Blocking one protein hands a tumor a problem it can often solve its way around. Acting on the programs behind its growth is a harder puzzle, and it opens the door to several tumor types.

Human Data, Not a Slide Deck

GZ17-6.02 has been through a Phase 1 study and advanced into Phase 1B work at Virginia Commonwealth University. Management will walk through where that stands.